Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Open accessThe DOI matches its Crossref record; 141 of the 145 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio–metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP‐1 receptor agonists, including liraglutide, semaglutide, and tirzepatide (dual GIP/GLP agonists), have revolutionised the field of obesity pharmacotherapy by facilitating substantial weight loss, achieving an average reduction of 9% with liraglutide, up to 15% with semaglutide, and 18% with tirzepatide [11, 12].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a critical consideration, as GLP-1RA treatment duration in patients with obesity is highly variable, ranging up to 24 months depending on weight loss goals.18”
From GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis (2025) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs consistently demonstrate significant weight loss (mean reductions of 7–9 kg of body weight over a period of about a year) and improvements in BMI, waist circumference, blood pressure, and lipid profiles in both diabetic and non-diabetic populations (5–7, 10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk – often surpassing the short-term effects of exercise alone (4–10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“There were no significant differences in hospitalization rates for non-fatal myocardial infarction, non-fatal stroke, and heart failure between the liraglutide and placebo groups [89].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 21×
“The first approach aimed at prolonging the hal -life of GLP-1 y i h bitin its degradation by DPP-4 through the d vel pment of DPP-4 inhibitors.”
BackgroundInfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 2×
“9 kg) resulted in smaller changes [65].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613 · cited 2×
“sclerosis, heart failure [14], and atrial fibrillation [15], while metabolic complications in-”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Research works printed but not linked: 3
- 2006, Safety and mechanism of action of orlistat (tetrahydrolipstatin) as the first local antiobesity drug, J. Appl. Sci. Res., 2, 205
- Kanwal, 2021, Liraglutide for Weight Management, Critical Analysis of Efficacy and Side effects in Non diabetic, individuals with obesity: A Comprehensive Systematic Review, Middle East J. Fam. Med., 19, 72
- (2019). Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment) [Internet], Canadian Agency for Drugs and Technologies in Health.
Cited by
Items 101–200 of 294
Relationship between hepatic lipid accumulation and type 2 diabetes mellitus
Wang, Z., Zan, W., Fan, Z., & Wang, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118723 · Cited by 8
Zhang, J., Guan, X., Kong, M.-W., Xia, M., Yu, Y., & Zhang, C. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156433 · Cited by 9
Torensma, B., Hany, M., Aarts, E. O., Berends, F. J., van Wagensveld, B. A., Parmar, C. D., Shikora, S. A., & COHEN, R. V. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07870-0 · Cited by 9
Gut Feelings: The Critical Role of Interoception in Obesity and Disorders of Gut–Brain Interaction
Chang, L., Thaiss, C. A., Knight, Z. A., & Khalsa, S. S. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.002 · Cited by 7
Zhang, Z., Li, S., Dai, X., Li, C., Pengfei, S., Qu, J., Jiang, H., & Pan, B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119509 · Cited by 9
Muschler, K., Muschalek, R., & Hoyte, C. O. (2025) · Clinical Toxicology · doi:10.1080/15563650.2024.2444642 · Cited by 7
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 10
“…1.36–5.34) and 3. physiological improvement in FMD was supported mechanistic insights revealing an improvement in endothelial function in human and 3.30 GLP-1 RAs confer cardiovascular benefits through the following mechanisms: they ], umbilical cardiovascular cardiovascular benefits of GLP-1 RAs .”
BackgroundInfluentialYu, C.-C., Xanthavanij, N., Wang, T. H., See, X. Y., Chang, Y.-C., Chiang, C., Hsia, Y. P., Chang, C.-C., Yang, K. J., & Chiang, C. (2025) · JAAD reviews. · doi:10.1016/j.jdrv.2025.04.009 · Cited by 6
The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems
Antonič, K. G., & Zitzmann, M. (2025) · The Aging Male · doi:10.1080/13685538.2025.2601423 · Cited by 7
“The combined central and peripheral actions of GLP-1 RAs promote satiety, decrease hunger, and ultimately reduce food intake [49].”
Körei, A. E., Putz, Z., Vági, O. E., Tordai, D. Z., Menyhárt, A., Istenes, I., Horváth, V. J., & Kempler, P. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108668 · Cited by 7
Eraky, S. M., Ramadan, N. M., Atif, H. M., Mahmoud, A. M., & El‐Magd, N. F. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123327 · Cited by 7
A Semaglutida aplicada ao tratamento da obesidade: perspectivas clínicas na literatura
Zanatta, M. C. A., da Rocha, F. S., Fumagali, T. A. S., Backes, G. A., Sambini, T. B., Matsukuma, I. S., Martinez, G. A., Benedetti, A. T. S., & Pereira, L. A. (2023) · Research Society and Development · doi:10.33448/rsd-v12i9.43295 · Cited by 13
Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists
Shah, M. Y., Mohammad, A., Samejo, R. B. A., Rana, S., Singla, S., Aurangzeb, R. I., Tariq, M. M., Zamir, M. H., Farooq, U., Aurangzeb, R. F., et al. (2025) · Cureus · doi:10.7759/cureus.88334 · Cited by 6
“The sustained efficacy of GLP-1 RAs supports a paradigm shift in the clinical management of obesity, moving from short-term weight loss strategies to long-term pharmacotherapy for chronic disease control [16].”
Defining aging-associated factors that increase susceptibility to prostate cancer
Zhang, S., Lee, E., Bopardikar, S., & Goldstein, A. S. (2025) · Endocrine Related Cancer · doi:10.1530/erc-25-0026 · Cited by 5
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Ameer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
The ‘Obesity First’ approach: Redefining the future of healthcare
Mulder, C. J. J., Bayoumy, A. B., & Ansari, A. R. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01882-5 · Cited by 7
“The development of glucagon-like peptide-1 (GLP-1) receptor agonists marks a major shift in obesity treatment [24].”
Overeating: A Conundrum of Lipid Metabolism and Inflammation in Obesity and Cancer
Surumbayeva, A., Saiman, Y., & Astsaturov, I. A. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70104 · Cited by 6
“Notably, GLP ‐ 1 has demonstrated the ability to promote weight loss (Popoviciu et al. 2023), which has garnered significant attention within the medical community.”
Yadav, A., & Melkani, G. C. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-06022-y · Cited by 7
“These effects are believed to occur via central GLP-1 receptor activation, reduction in neuroinflammation, improved insulin sensitivity in the brain, and enhanced hippocampal neurogenesis [74 , 103 , 104].”
Ligand binding modes of the bitter taste receptor T2R14 and T2R46
Tan, Q., Yu, Y., Han, X., Liu, K., Han, S., Wang, M., Wei, Y., Zhu, Y. C., Chen, Q., Ma, L., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01786-8 · Cited by 7
Os possíveis efeitos adversos dos análogos de GLP-1 em pessoas não-diabéticas e não-obesas
Guerra, L. P. D. C., Antunes, E. M., & da Silva, R. E. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-357 · Cited by 6
Goel, A., Goel, P., & Goel, S. (2024) · Cureus · doi:10.7759/cureus.69669 · Cited by 6
“Agents such as metformin and glucagon-like peptide 1 (GLP-1) receptor agonists target weight reduction and improve metabolic parameters [20,21].”
BackgroundKim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
“In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated effective weight loss outcomes, and upcoming drugs such as GLP-1 RA combination agents have also raised expectations for effective weight loss [27,28].”
Bołdys, A., Borówka, M., Bułdak, Ł., & Okopień, B. (2025) · Metabolites · doi:10.3390/metabo15080510 · Cited by 6
Singh, G., Ansari, S., & Aran, K. R. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01697-5 · Cited by 5
“However, research continues to discover whether other GLP-1 receptor agonists would be better, particularly for specific patient groups (Popoviciu et al. 2023).”
Neurolysin Knockout Mice in a Diet-Induced Obesity Model
Caprioli, B., Eichler, R. A. D. S., da Silva, R. D. N. O., Martucci, L. F., Reckziegel, P., & Ferro, E. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015190 · Cited by 5
PERDA DE PESO ASSOCIADA AO USO DE SEMAGLUTIDA: EFICÁCIA E MECANISMO DE AÇÃO
Leite, A. M. C. S., Fraga, L. A., Filho, T. B. M. P., Rangel, A. L. D. A., Gonzaga, Í. C., de Mello, M. E. L. B., Souza, V., Júnior, J. P. D. O., Lins, M. L. N., Aleixo, G. H., et al. (2023) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2023v5n5p3095-3103 · Cited by 5
Tu, S., Chen, J. Z., Singh, S. R. K., Maraboyina, S., Gökden, N., Hsu, P.-C., & Langford, T. (2024) · Cancers · doi:10.3390/cancers16030624 · Cited by 6
Scarlett McNally: Preventing obesity is different from curing it—and even more urgent
McNally, S. A. (2024) · BMJ · doi:10.1136/bmj.q134 · Cited by 5
Baran, K., Jankowska, M., Jańczyk, N., Mędrysa, K., Pokrzepa, J. J., Presak, M., Blecharz, G., Szwech, J., Winkowska, A., & Machalica, J. (2024) · Quality in Sport · doi:10.12775/qs.2024.30.56469 · Cited by 4
Mróz, M., Sadowska, D., Zarychta, M., Iwanowicz-Palus, G., Kretowski, A. J., & Cybulski, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061883 · Cited by 7
“GLP-1 analogue reduces appetite and improves metabolism, which leads to weight loss [35].”
Alali, S., Alotaibi, W. S., Ashodian, K., Achour, N., Almulla, A., & Mutlaq, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1590379 · Cited by 5
Li, W., Cai, R., Yin, B., Zhou, Y., Dong, X., Li, W., & Wen, J. (2025) · Biology · doi:10.3390/biology14050575 · Cited by 4
“For example, semaglutide, a second-generation GLP-1 receptor agonist, was approved by the Food and Drug Administration (FDA) in 2021 for the treatment of obesity in adults with a body mass index (BMI) ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with body weight-related complications [10].”
Kadharusman, M. M., Syahputra, R. A., Kurniawan, R., Hadinata, E., Tjandrawinata, R. R., Taslim, N. A., Romano, R., Santini, A., & Nurkolis, F. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01823-4 · Cited by 5
“The decreased expression of SREBP-1c, a key regulator of lipid synthesis in the liver, implies reduced lipid accumulation and a protective effect against hepatic steatosis [3–5].”
Aspiration Risk During Endoscopic Procedures While on GLP-1 Agonist Therapy
Stryelkina, M., Molina, R., Janice, T., Ancha, A., Bejcek, J., Ian, F., Mullarkey, M., & Johnson, C. T. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09307-1 · Cited by 4
Advances in Microneedle Drug Delivery for Obesity: Mechanisms, Applications, and Perspectives
Wu, C., Zong, Z., Hua, F., Wu, J., Shen, Y., Tian, Y., & Chen, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s566132 · Cited by 5
“88 Since T2DM is a common comorbidity of obesity, therapies that simultaneously improve glycemic control and reduce body weight are of great clinical value.”
Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Abbasi, M., Sun, K., Huggins, K. W., Heath, B., DeLoit, H., McGinness, L., & Mccamy, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.035 · Cited by 10
“In obesity, GLP-1RAs promote weight loss primarily by reducing food intake and increasing satiety, while also improving adipose tissue metabolism and reducing inflammation 42 .”
Ahmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study
Bar, D., Pavlotsky, F., Baum, S., & Barzilai, A. (2026) · JAAD International · doi:10.1016/j.jdin.2026.04.004 · Cited by 4
The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review
Corcoran, E., Kettlety, M., Mogul, U., Azah, J. N., & Cork, S. C. (2026) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2026.104091 · Cited by 6
Frailty syndrome in older adults: Research advances and management strategies
Yu, G., Hu, Y. M., Chen, R., Yang, Y., Hu, C. H., Yao, H., & Su, Y. (2026) · iScience · doi:10.1016/j.isci.2026.116264 · Cited by 6
“116 By reducing visceral adiposity and systemic inflammation, these agents may indirectly benefit physical function and iScience Review metabolic health in frail individuals.”
The effect of incretin-based drugs on the riks of acute pancreatitis: a review
Czaplicka, A., & Kaleta, B. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01430-6 · Cited by 4
“Albiglutide, dulaglutide and semaglutide are injected once a week, while oral sema - glutide is used once daily [18].”
Aboaba, A. O., Okoro, M. C., Okobi, O. E., Falade, I. M., Ogbeifun, O. E., Katas, S., Agbodike, K., Ogbebor, U. P., & Fashugba, M. A. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.127003 · Cited by 6
Mental Health Implications of Weight Loss Medications: A Narrative Review
Harding, S. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105207 · Cited by 44
Anthropometric Trajectories and Dietary Compliance During a Personalized Ketogenic Program
García-Gorrita, C., Soriano, J. M., Merino-Torres, J. F., & Onofre, N. S. (2025) · Nutrients · doi:10.3390/nu17091475 · Cited by 4
Petty, L., Soto‐Pedre, E., McCrimmon, R. J., & Pearson, E. R. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108747 · Cited by 4
Nguyen, T. T., & Elmaleh, D. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030812 · Cited by 3
“Interestingly, many of these were approved for the management of T2D before they were evaluated for obesity and overweight [35].”
Kamrul-Hasan, A. B. M., Ganakumar, V., Nagendra, L., Dutta, D., Islam, M. R., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.103244 · Cited by 4
Liechti, M., Schurz, A. P., Marnef, A. Q., Taeymans, J., Clijsen, R., Baur, H., Lutz, N., Deliens, T., Clarys, P., Nijs, J., et al. (2025) · Physical Therapy · doi:10.1093/ptj/pzaf097 · Cited by 3
“77,78 82 Moreover, access to these medications remains limited, not all patients are eligible to obtain them, and they are typically prescribed alongside mandatory lifestyle and dietary changes.”
Stump, K., Kelleher, S., Hannah, T. C., Patel, N., Kanuparthi, P., Vij, R., & Kim, B.-S. (2025) · Global Spine Journal · doi:10.1177/21925682251396965 · Cited by 7
“18 Further, given the known risks of obesity on postoperative outcomes, these therapies have been suggested for preoperative optimization of obese patients while also demonstrating favorable effects on markers of bone metabolism.”
Thapa, G., Barbhuiya, P. A., & Pathak, M. P. (2026) · Current Nutrition Reports · doi:10.1007/s13668-025-00718-0 · Cited by 3
“…rs6235), BDNF (rs6265, rs10767664), PPARG (rs1801282), ENPP1 (rs1044498, K121Q), TBC1D1 (rs12502572, R125W), and GPR120 (rs116454156, R270H), which exert modest but tirzepatide, Exenatide are the GLP-1 agonists [119] that suppress appetite after meal by the release of GLP from the intestinal lumen.”
Mercadal-Orfila, G., Taltavull, J. L., Cuatrecasas, G., García, J. M., Maestre-Fullana, M. A., & Herrera-Pérez, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1731194 · Cited by 5
Salingaros, S., Zhang, A., Rohde, C. H., & Spector, J. A. (2026) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000004657 · Cited by 4
Gonciarz, M. J., Adamiec, D. K., Dąbrowska, A., Paduszyńska, N., Zaliwska, D., Czach, M., Strojny, A. A., Kraszkiewicz, A., Kamińska, M. A., & Do, M. K. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52871 · Cited by 5
Heimann, A. S., Singh, P., Ferro, E. S., Greenway, F. L., & Krongrad, A. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70056 · Cited by 4
“…represents a mechanistically distinct approach to weight management, particularly for individuals unable to tolerate conventional therapies, such as glucagon‐like peptide‐1 (GLP‐1) receptor agonists (e.g., semaglutide and tirzepatide), which are associated with significant lean mass loss [48, 49].”
Benefits of Supplementing a GLP-1 Type Medication With Physical Activity
Ablah, E. A., Imboden, M. T., Zendell, A. L., Hosking, M., Anderson, R. E., VanHoose, K., Peterson, N. E., Wojcik, J. R., Pronk, N. P., Harber, M., et al. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251357130 · Cited by 3
“12 For the purposes of this paper, we use “ GLP-1 type medications ” to describe GLP-1 RAs (e.g., liraglutide, semaglutide, exenatide), the dual agonist medications (GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), e.g., tirzepatide), and triple agonist medications (GLP-1 RA, GIP RA,…”
Gherbon, A., Frandeș, M., Nicula, M., Timar, R. Z., & Timar, B. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s434990 · Cited by 4
Bosworth, K. T., Ghosh, P., Flowers, L., Proffitt, R. M., Koopman, R. J., Tosh, A. K., Wilson, G., & Braddock, A. S. (2024) · Frontiers in Digital Health · doi:10.3389/fdgth.2024.1396085 · Cited by 5
“This is especially true with the rise of glucagon-like peptide 1 (GLP-1) agonists for weight loss, while effective (26), are often expensive (27) and inaccessible to many.”
BackgroundDrug treatments to prevent first decompensation in cirrhosis
Kezer, C. A., Berzigotti, A., Fortune, B. E., & Simonetto, D. A. (2024) · Hepatology · doi:10.1097/hep.0000000000001117 · Cited by 4
Alghamdi, F. A., Alshegifi, H., Alhuthayli, R., Helal, T., Huwait, T. A., Alharbi, T., Akbar, A. F., Alshehri, W., & Alsheikh, S. (2024) · Cureus · doi:10.7759/cureus.74345 · Cited by 3
Ensuring safety first: GLP ‐ 1RAs in reproductive and endometrial research
Viganò, P., Casalechi, M., Salonia, A., & Somigliana, E. (2025) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.15060 · Cited by 3
Khare, S., Osumili, B., Debackere, N., Keapoletswe, K., Falato, S., Raoul, T., & Coles, B. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03002-9 · Cited by 4
“Moreover, many healthcare providers prescribe GLP-1 RAs on the basis of the clinical outcomes glycemic control and weight loss response jointly [18].”
Jo, D., Ahn, S. Y., Choi, S. Y., Choi, Y., Lee, D. H., & Song, J. (2024) · Clinical Nutrition Research · doi:10.7762/cnr.2024.13.2.121 · Cited by 2
“…peptide-1 (GLP-1), a glycoprotein hormone produced by gut L-cells and specific neurons in the nucleus tractus solitarius of the brain [16], improves impaired glucose metabolism, reduces the sensation of hunger, and reduces food intake in patients with metabolic syndrome and obesity [17].”
BackgroundBeak, J. Y., Lee, K., Im, B. N., Kwon, T. K., Im, H. T., Cho, J. H., & Cho, H. J. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00752-8 · Cited by 2
“Glucagon-like peptide-1 (GLP-1)-based therapies have gained significant attention as a leading treatment option, achieving approximately 15% weight reduction along with improved blood glucose control compared with the placebo group (Popoviciu et al. 2023).”
Association between visceral adiposity index and oral health status in a National survey
Liu, J., Shuning, L., & Yang, W. Y. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-11803-3 · Cited by 2
“It is closely linked to cardiovascular diseases 47 including hypertension and coronary artery disease, with a notable increase in risk for heart failure 48 syndrome 49,50 .”
Zohora, F. T., Mou, S. S., Haque, M. R., Baidya, M., Jahan, I., & Al-Mamun, M. E. (2025) · Translational Medicine of Aging · doi:10.1016/j.tma.2025.08.005 · Cited by 2
Hoang, M., Mirza, F. N., Abrantes, T. F., Gorrepati, P. L., & Libby, T. J. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-04379-5 · Cited by 2
Nahar, S., Maybee, N. A., Tamanna, N., Sadat, A., Khanam, F., Begum, R., Akther, S., Khan, M. S., Sonia, S. N., & Hasan, N. (2025) · Cureus · doi:10.7759/cureus.98935 · Cited by 2
“Initially developed solely for the management of diabetes, GLP-1 RAs are now widely recognized for their effectiveness in reducing body weight [2].”
The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review
Gala, D., Botros, F., & Makaryus, A. N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45204 · Cited by 3
“Beyond glucose lowering, GLP-1 RAs induce satiety and promote weight loss, addressing the obesity-diabetes nexus that exacerbates insulin resistance and complicates disease management [7,8].”
Jan, A., & Dubwa, D. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100272 · Cited by 2
Ghosal, S., & Ghosal, A. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100281 · Cited by 2
“Our results are consistent with prior evidence that GLP-1RA-based therapies achieve significant reductions in visceral adiposity and WC beyond the effects of weight loss alone [47].”
Miertová, Z., Lecký, P., Focko, B., Bolek, T., Péč, M. J., Jurica, J., Nagy, N., Galajda, P., Mokáň, M., & Samoš, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-56147-8 · Cited by 2
“GLP-1 RA have several effects on various organ systems, combining central and peripheral actions that promote satiety, decrease hunger, decrease appetite, and ultimately lead to reduced food intake 4 .”
Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review
López-Delgado, D. S., Reyes-Zermeño, M. G., Lemus, E. D. S., Acosta-Celis, C. G., Kantún-Marín, M. A., Gomez-Lujan, M., Fallaza-Moya, K., Muñoz-Chuquilín, O., Levano, S. E. T., Gutierrez-Chavez, G., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1803474 · Cited by 2
“These findings suggest that individual differences in glucose–insulin regulatory pathways may influence the effectiveness of certain AOMs (57).”
Glucagon-like peptide-1 receptor agonists and hair loss: Current evidence and potential mechanisms
Spindler, A. J., Maas, D., Rachko, G., Zappi, I., Kapur, S. K., Sidhu, K. S., Maas, K., Garza-García, L. M., Patrocínio, J., Petukhova, L., et al. (2026) · JAAD reviews. · doi:10.1016/j.jdrv.2026.07.002 · Cited by 2
Relationship between hyperleptinemia and cardiometabolic risk in persons with obesity
Chernyavska, I. V., Кравчун, Н. А., Дунаєва, І., Tykha, I. A., Oliynikova, S. P., & Rassolova, O. S. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.1.2024.1358 · Cited by 2
A Structured Social Media Health Support Program after Bariatric Surgery
Tamir, O., Kais, H., Accos-Carmel, M., Kolobov, T., Matthews, G., Lipsits, A., Shalev, Y., Sheffer-Benton, S., & Benis, A. (2024) · Applied Clinical Informatics · doi:10.1055/a-2395-3357 · Cited by 3
“49,50 As such, bariatric surgery will remain relevant for many people, especially due to the high number of adults classi fi ed as obese.”
Leggat-Barr, K., Yee, D., Duralde, E. R., Hodge, C., Borges, V. F., Baxter, M., Valdez, J. M., Morgan, T., Garber, J. E., & Esserman, L. J. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07522-4 · Cited by 4
Sun, Y., Li, S., Liu, R., Ma, N., Zhao, X., & He, X. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106834 · Cited by 4
Sahu, M., Szpiro, A. A., van Rooyen, H., Asiimwe, S. B., Shahmanesh, M., Roberts, D. A., Krows, M. L., Sausi, K., Sithole, N., Schaafsma, T. T., et al. (2025) · Journal of the International AIDS Society · doi:10.1002/jia2.26513 · Cited by 2
Towards a better mouse model of vertical sleeve gastrectomy
Blok, N. B., Evers, S. S., Lewis, A. G., Toure, M. H., Bozadjieva-Kramer, N., Seeley, R. J., & Myronovych, A. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.06.017 · Cited by 2
Tapper, E. B., Ryan, T., Zeng, N., Carter, R., Winer-Jones, J. P., Bonafede, M., & Kim, Y. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0223 · Cited by 2
Drug-Based Strategies for Weight Reduction and Their Interaction with the Human Gut Microbiota
Lee, V., Kim, E., & Singh, J. (2025) · Annals of Pharmacy Practice and Pharmacotherapy · doi:10.51847/oobvhfczjv · Cited by 2
Body Mass Index, Comorbidities, and Ambulatory Care Visits: The REGARDS Study
Levitan, E. B., Zhu, A., Bittner, V., Brown, T. M., Farkouh, M. E., Girguis, M. S., Huang, L., Jackson, E. A., Judd, S. E., Rhodes, S. L., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037034 · Cited by 1
“34,35 However, many of these trials included participants with significantly lower average age than the current study population and the broader population of people with Medicare coverage.”
Josefine, R., Schilliger, L., Athanasios, K., Cathrin, R., Böhm, S., Haidinger, M., Fischler, M., & Jensen, A. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.10.005 · Cited by 1
Ahmad, B., Singh, P., Shah, R. J., Arif, M. H., Goel, A., Saeed, M., Saleh, A. O., Amer, S., Mukhlis, M., Waqas, S. A., et al. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102628 · Cited by 1
Park, A. K., Hom, J., Lorenzo, J., Rao, V. K., Hui, G., Vickers, M., & Ahuja, N. K. (2025) · Journal of Hospital Medicine · doi:10.1002/jhm.70228 · Cited by 2
The development status and research progress of hypoglycemic peptides: A review
Zhao, W., Zhao, X., Li, Y., Yu, B., & Cong, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149859 · Cited by 1
Glucagon-like peptide-1 receptor agonists across anti-inflammation
Chen, D. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101474 · Cited by 1
Bcharah, G., Wininger, A. E., Tarabichi, S., Elsabbagh, Z., Verhey, J. T., Christopher, Z. K., Clarke, H. D., Spangehl, M. J., & Bingham, J. S. (2026) · The Journal of Arthroplasty · doi:10.1016/j.arth.2026.04.032 · Cited by 1
Lakhani, D. A., & Zheng, W. (2026) · Journal of Addictive Diseases · doi:10.1080/10550887.2026.2653228 · Cited by 1
Uso da semaglutida com fins emagrecedores por indivíduos não diabéticos
Pires, S., Leal, B. A., Souza, I. P., Rangel, K. C. F., & Filho, L. E. D. S. (2023) · Research Society and Development · doi:10.33448/rsd-v12i12.43905 · Cited by 6
Pathophysiological mechanisms of varicose veins in the lower extremities
Kolosovych, І. V., Korolova, K. O., & Korolova, Z. V. (2025) · Fìzìologìčnij žurnal · doi:10.15407/fz71.01.079 · Cited by 2
“This hypothesis is supported by data that obesity, multiple fertility, and professions that require prolonged standing are strong risk factors for the development of VDLE [18, 19].”
Exploring the off-label use of liraglutide in the treatment of obesity: a review
Braga, C. B. A., Segundo, J. P. V. A., & Filho, C. A. A. D. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05560-8 · Cited by 1
Gone, G. B., Kim, Y., Song, Y., Nam, G., Park, S. H., Lee, H., & Chung, S. J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108875 · Cited by 1
Peptidic Tryptophan Halogenation by a Promiscuous Flavin‐Dependent Enzyme
Rice, A. J., Gadgil, M. G., Bisignano, P., Stein, R. A., Mchaourab, H. S., & Mitchell, D. A. (2025) · Angewandte Chemie · doi:10.1002/ange.202509729 · Cited by 1
Popoviciu, M. S., Reurean‐Pintilei, D., Salmen, T., Rus, M., Ferician, A. C., Sava, C. N., Ardelean, A. I., Moroianu, L.-A., & Stoian, A. P. (2025) · Biomedicines · doi:10.3390/biomedicines13092174 · Cited by 1
“Despite sustained global efforts, obesity prevalence continues to rise, and no country within the European Union or the United States has successfully reversed this trend [49–52].”
Self-citationQin, Y., Xv, X., Cheng, L., & Liu, B. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04748-z · Cited by 2
Tekengne, B. O. T., Eke, C. I., Cumaaran, C., Ozigbo, A. A., Okoyeuzu, C., Okhagbuzo, I. M., Sadiq-Onilenla, R. A., & Okobi, O. E. (2025) · Cureus · doi:10.7759/cureus.91722 · Cited by 2
“Drugs most likely to be helpful in the future include glucagon-like peptide-1 (GLP-1) receptor agonists, a subgroup of drugs initially used to control glycemic levels in patients with type 2 diabetes mellitus (T2DM) [10].”
Jaradat, J. H., Alahmad, R., Jaghbeer, M. A., Abdelaziz, A. A., Afifeh, N. A., Afifeh, G. A., Rao, A., Alzoubi, A., & Nashwan, A. J. (2025) · Cureus · doi:10.7759/cureus.96071 · Cited by 3
Bajpai, J., Saxena, M., Agarwal, U., & Pradhan, A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i4.109762 · Cited by 1
“%) than non-users (12.56%, P < 0.001)[50].”
Influential
Metadata
- Authors
- Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S.
- Affiliations
- University of Oradea (RO)
- University of Kaiserslautern (DE)
- Zagazig University (EG)
- Corresponding author
- Cavalu, Simona
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-21
- Volume
- 24
- Issue
- 13
- Pages
- 10449
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10341852
- OpenAlex
- W4381618228
- Semantic Scholar
- f13196d495574d64dbe2e547bd587bb48816b847
- Cited by
- 280
- References
- 145
- Citations by year
- 2026: 70 · 2025: 131 · 2024: 67 · 2023: 12
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Oradea
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, weight loss, type 2 diabetes, hyperglycemia, insulin sensitivity, blood pressure, cardioprotection, renal protection, obesity-related comorbidities, long-term safety, non-diabetic patients
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Peptides, Weight Loss, Randomized Controlled Trials as Topic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.